HUP9702408A3 - Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition - Google Patents

Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition

Info

Publication number
HUP9702408A3
HUP9702408A3 HU9702408A HUP9702408A HUP9702408A3 HU P9702408 A3 HUP9702408 A3 HU P9702408A3 HU 9702408 A HU9702408 A HU 9702408A HU P9702408 A HUP9702408 A HU P9702408A HU P9702408 A3 HUP9702408 A3 HU P9702408A3
Authority
HU
Hungary
Prior art keywords
phenyloxazolidin
tnf
inhibition
derivatives
preparation
Prior art date
Application number
HU9702408A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HUP9702408A2 publication Critical patent/HUP9702408A2/hu
Publication of HUP9702408A3 publication Critical patent/HUP9702408A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
HU9702408A 1995-02-10 1996-02-09 Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition HUP9702408A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19505516 1995-02-10

Publications (2)

Publication Number Publication Date
HUP9702408A2 HUP9702408A2 (hu) 1998-05-28
HUP9702408A3 true HUP9702408A3 (en) 2000-08-28

Family

ID=7754327

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9702408A HUP9702408A3 (en) 1995-02-10 1996-02-09 Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition

Country Status (14)

Country Link
US (1) US6117895A (hu)
EP (1) EP0804192A1 (hu)
JP (1) JPH11500110A (hu)
KR (1) KR19980702116A (hu)
CN (1) CN1173818A (hu)
AU (1) AU706159B2 (hu)
CZ (1) CZ290671B6 (hu)
FI (1) FI973277A (hu)
HU (1) HUP9702408A3 (hu)
IL (1) IL117090A (hu)
MX (1) MX9706086A (hu)
SK (1) SK283821B6 (hu)
WO (1) WO1996024350A1 (hu)
ZA (1) ZA961081B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8747998A (en) * 1997-08-21 1999-03-16 Takeda Chemical Industries Ltd. Anti-inflammatory agent
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
AR057218A1 (es) * 2005-12-15 2007-11-21 Astra Ab Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
FR2358155A1 (fr) * 1976-07-15 1978-02-10 Lapinet Eugene Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses
DE2655369A1 (de) * 1976-12-03 1978-06-08 Schering Ag 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung
DE3438839A1 (de) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
US5783591A (en) * 1984-10-19 1998-07-21 Schering Aktiengesellschaft Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
DE3639225A1 (de) * 1986-11-14 1988-05-19 Schering Ag Verwendung von 5-(subst. phenyl)-oxazolidinonderiaten als psychopharmaka
AU6355190A (en) * 1989-06-13 1991-01-17 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
ATE161720T1 (de) * 1990-08-03 1998-01-15 Smithkline Beecham Corp Tnf-inhibitoren
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5227369A (en) * 1991-07-11 1993-07-13 The Regents Of The University Of California Compositions and methods for inhibiting leukocyte adhesion to cns myelin
GB9204808D0 (en) * 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis

Also Published As

Publication number Publication date
HUP9702408A2 (hu) 1998-05-28
IL117090A0 (en) 1996-06-18
ZA961081B (en) 1996-10-15
SK283821B6 (sk) 2004-02-03
US6117895A (en) 2000-09-12
FI973277A0 (fi) 1997-08-08
AU706159B2 (en) 1999-06-10
IL117090A (en) 2000-07-26
FI973277A (fi) 1997-08-08
CZ251397A3 (en) 1997-12-17
CN1173818A (zh) 1998-02-18
MX9706086A (es) 1997-10-31
SK107397A3 (en) 1997-12-10
KR19980702116A (ko) 1998-07-15
AU4712296A (en) 1996-08-27
JPH11500110A (ja) 1999-01-06
CZ290671B6 (cs) 2002-09-11
EP0804192A1 (de) 1997-11-05
WO1996024350A1 (de) 1996-08-15

Similar Documents

Publication Publication Date Title
AU4067697A (en) Therapeutic compositions for treatment of cancer
HUP9900773A3 (en) Use of carbazole derivatives for producing pharmaceutical compositions suitable for the treatment of congestive heart failure
IL121170A0 (en) Compositions for the treatment of dermatological disorders
IL117957A0 (en) Pharmaceutical compositions for the treatment of impotence
HUP9903489A3 (en) Use of epinastine for the preparation of pharmaceutical compositions treating pain
HUT70034A (en) Process for preparing pharmaceutical compositions containing dipyridamole for the treatment of proliferative diseases
HUP9803018A3 (en) Use of cyclooxygenase-2 inhibitors for producing pharmaceutical compositions suitable for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
HUT64047A (en) Process for producing compounds and pharmaceutical compositions suitable for the simultaneous inhibition of no-syntase and cyclogenase
HUP9603607A3 (en) Use of triazolidine derivatives for the preparation of pharmaceutical compositions for the treatment and prophylaxis of osteoporosis
IL113263A0 (en) Imidazo pyridine compounds and pharmaceutical compositions for the treatment of gastrointestinal diseases
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
AU6858996A (en) Pharmaceutical compositions for the treatment of infectious diseases
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
HUP0003679A3 (en) Use of pkc inhibitors for the preparation of pharmaceutical compositions treating cardiovascular diseases
HUP9903684A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating depression
HUP9702408A3 (en) Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition
IL121096A0 (en) Pharmaceutical compositions for the treatment of liver disease
HUP9900309A3 (en) Use of ridogrel for producing pharmaceutical compositions for the treatment of inflammatory bowel diseases
HUP9901247A3 (en) Use of naphthimidazole-, naphthoxazole- and naphthothiazole-diones for the preparation of pharmaceutical compositions treating diseases caused by vascular function deficiency
AU3027692A (en) Compositions for the treatment of mammalian diseases
IL106751A0 (en) Pharmaceutical compositions for the treatment of reversible obstructive airways diseases
HU895948D0 (en) Process for the preparation of dipeptidecarbamide derivatives having inhibition of renine and pharmaceutical compositions thereof
ZA943342B (en) The use of compositions for combating tumour diseases
AU1228499A (en) Application of tnf antagonists as medicaments for treating septic diseases
HUP9801925A3 (en) Use of sodium-hydrogen-exchange-inhibitors for producing pharmaceutical compositions treating diseases caused by protozoons